Interim analyses may lead to early stopping if which conditions are met?

• A. Efficacy or safety concerns
• B. Budget constraints
• C. Investigator turnover
• D. Data quality issues

Answer: (A)

Interim analyses are planned checks of trial data partway through the study, used to decide whether the trial should continue as planned or stop early. They may lead to stopping when there is clear evidence of benefit, meaning the treatment works well enough that continuing won’t change the overall conclusion and would delay bringing an effective therapy to patients. They may also lead to stopping when safety concerns arise, indicating that the risks to participants are unacceptable or outweigh potential benefits, so continuing would expose people to undue harm.

These stopping decisions are guided by predefined boundaries to maintain trial integrity and control error rates, typically overseen by an independent data monitoring committee. Budget constraints or investigator turnover aren’t criteria for stopping based on the trial’s results, and data quality issues would more commonly trigger corrective actions or study suspension rather than a decision to stop for efficacy or safety.